(Q36700047)

15 August 2017

1 reference

title

Drug Insight: the use of intravenous immunoglobulin in neurology--therapeutic considerations and practical issues (English)

1 reference

15 August 2017

1

Ralf Gold

1 reference

15 August 2017

Martin Stangel

2

1 reference

15 August 2017

Marinos C Dalakas

series ordinal

3

1 reference

15 August 2017

publication date

1 January 2007

1 reference

Nature Clinical Practice Neurology

15 August 2017

published in

1 reference

15 August 2017

volume

3

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

36-44

1 reference

https://scigraph.springernature.com/pub.10.1038/ncpneuro0376

15 August 2017

exact match

0 references

cites work

Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

How long is IVIg effective in multifocal motor neuropathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

Reduced levels of amyloid beta-peptide antibody in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

Intravenous immune globulin therapy for neurologic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Immunotherapy in autoimmune neuromuscular disorders

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

CD4+ CD25+ suppressor T cells: more questions than answers

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Intravenous immunoglobulin and dendritic cells.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

[Use of i.v. immunoglobulins in neurology. Evidence-based consensus]

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

A study of 20 SLE patients with intravenous immunoglobulin--clinical and serologic response

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barré Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Treatment of Myasthenia Gravis Exacerbation With Intravenous Immunoglobulin

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

High-Dose Intravenous Immune Globulin for Stiff-Person Syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Prior poliomyelitis-evidence of cytokine production in the central nervous system

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Prior poliomyelitis-IVIg treatment reduces proinflammatory cytokine production

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Narcolepsy and the hypocretin system--where motion meets emotion

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Follow-up of four narcolepsy patients treated with intravenous immunoglobulins

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Side effects of intravenous immunoglobulins in neurological autoimmune disorders--a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Reversible encephalopathy with cerebral vasospasm in a Guillain-Barré syndrome patient treated with intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Review: intravenous immunoglobulin therapy and thromboembolic complications

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Arterial thrombosis induced by IVIg and its treatment with tPA

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

The clinical features of 16 cases of stroke associated with administration of IVIg

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Intravenous immunoglobulin: adverse effects and safe administration

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Acute renal failure following immunoglobulin therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Intravenous immunoglobulin-induced osmotic nephrosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0376

7 January 2021

Identifiers

DOI

10.1038/NCPNEURO0376

1 reference

Dimensions Publication ID

15 August 2017

1039324495

0 references

1 reference